Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N7-butyl-N2-(5-chloro-2-methylphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidine-2,7-diamine is a synthetic small molecule belonging to the triazolopyrimidine class of polycyclic aromatic compounds. It has not been approved for any medical use and is considered an experimental compound. There are no known clinical indications or trials involving this molecule as of now. Its mechanism of action and pharmacological targets have not been described in the available literature or databases. The compound is referenced in chemical and drug discovery databases such as DrugBank (DB07128) and ChEMBL (ChEMBL380589), but no further biological or therapeutic information is provided.[1][3][6][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N7-butyl-N2-(5-chloro-2-methylphenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidine-2,7-diamine.